Wall Street Zen cut shares of Sol Strategies (NASDAQ:STKE – Free Report) from a sell rating to a strong sell rating in a report issued on Sunday,Wall Street Zen reports.
Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald upped their price objective on Sol Strategies from $2.80 to $6.20 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Weiss Ratings lowered Sol Strategies from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Sol Strategies has a consensus rating of “Hold” and an average price target of $6.20.
Read Our Latest Report on Sol Strategies
Sol Strategies Price Performance
Institutional Investors Weigh In On Sol Strategies
An institutional investor recently raised its position in Sol Strategies stock. Key Client Fiduciary Advisors LLC lifted its stake in Sol Strategies (NASDAQ:STKE – Free Report) by 7.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 356,387 shares of the company’s stock after buying an additional 25,800 shares during the quarter. Key Client Fiduciary Advisors LLC’s holdings in Sol Strategies were worth $417,000 at the end of the most recent reporting period.
About Sol Strategies
Sol Strategies Inc is a company focused on building and supporting infrastructure and services for the Solana blockchain ecosystem. Its business is centered on providing exposure to and operational support for digital asset network participation, including activities associated with staking and related blockchain infrastructure.
The company has positioned itself as part of the broader cryptocurrency and decentralized finance landscape, where blockchain validators and staking operations play a role in helping secure proof-of-stake networks.
Featured Articles
- Five stocks we like better than Sol Strategies
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Sol Strategies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Strategies and related companies with MarketBeat.com's FREE daily email newsletter.
